Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

CDX2, Cytokeratins 7 and 20 Immunoreactivity in Rectal Adenocarcinoma

CDX2, Cytokeratins 7 and 20 Immunoreactivity in Rectal Adenocarcinoma Downloaded from http://journals.lww.com/appliedimmunohist by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/10/2020 RESEARCH ARTICLE CDX2, Cytokeratins 7 and 20 Immunoreactivity in Rectal Adenocarcinoma Reda S. Saad, MD, PhD, FRCPC,* Jan F. Silverman, MD,w Mahmoud A. Khalifa, MD,* and Corwyn Rowsell, MD* etastatic cancer of unknown origin accounts for Abstract: There are limited data regarding CDX2 expression in Mapproximately 3% to 5% of all malignant neo- rectal carcinoma. The CK20/CK7 immunoprofile of colorectal plasms and constitutes 1 of the 10 most frequent cancer adenocarcinoma has been described in studies, which have diagnoses in humans. About 5% to 15% of cancer mostly lumped colonic and rectal tumors together. In this study, patients may initially present with a clinical picture we investigated the diagnostic utility of immunohistochemical related to metastases, rather than to their primary 2–5 stains for CK7, CK20, and CDX2 in a series of rectal tumor The identification of the primary site of adenocarcinoma. Fifty-five specimens of rectal adenocarcino- metastatic tumor could lead to more effective treatment, mas were retrieved and immunostained for CK7 (Dako-M7018), improving the overall outcome. Although modern ima- CK20 (NovoCastra NCL-L-CK20), and CDX2 (NovoCastra ging technology has improved our ability to identify the NCL-CDX2). Thirty cases of pancreatic adenocarcinoma and origin http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

CDX2, Cytokeratins 7 and 20 Immunoreactivity in Rectal Adenocarcinoma

Loading next page...
 
/lp/wolters-kluwer-health/cdx2-cytokeratins-7-and-20-immunoreactivity-in-rectal-adenocarcinoma-urKGkYkzhC
Publisher
Wolters Kluwer Health
ISSN
1541-2016
DOI
10.1097/PAI.0b013e31819268f2
Publisher site
See Article on Publisher Site

Abstract

Downloaded from http://journals.lww.com/appliedimmunohist by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/10/2020 RESEARCH ARTICLE CDX2, Cytokeratins 7 and 20 Immunoreactivity in Rectal Adenocarcinoma Reda S. Saad, MD, PhD, FRCPC,* Jan F. Silverman, MD,w Mahmoud A. Khalifa, MD,* and Corwyn Rowsell, MD* etastatic cancer of unknown origin accounts for Abstract: There are limited data regarding CDX2 expression in Mapproximately 3% to 5% of all malignant neo- rectal carcinoma. The CK20/CK7 immunoprofile of colorectal plasms and constitutes 1 of the 10 most frequent cancer adenocarcinoma has been described in studies, which have diagnoses in humans. About 5% to 15% of cancer mostly lumped colonic and rectal tumors together. In this study, patients may initially present with a clinical picture we investigated the diagnostic utility of immunohistochemical related to metastases, rather than to their primary 2–5 stains for CK7, CK20, and CDX2 in a series of rectal tumor The identification of the primary site of adenocarcinoma. Fifty-five specimens of rectal adenocarcino- metastatic tumor could lead to more effective treatment, mas were retrieved and immunostained for CK7 (Dako-M7018), improving the overall outcome. Although modern ima- CK20 (NovoCastra NCL-L-CK20), and CDX2 (NovoCastra ging technology has improved our ability to identify the NCL-CDX2). Thirty cases of pancreatic adenocarcinoma and origin

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: May 1, 2009

There are no references for this article.